Dr. Deepak Kumar Bandari, PharmD : Short Profile

Thank you for visiting my blog...!!!

Here you can check out my short profile 

Dr. Deepak Kumar Bandari, PharmD, (PhD) (Europe)

Research Scientist, ICMR-NICPR, Noida.

Current Position: National

1) Project Research Scientist - Indian Council of Medical Research (ICMR) - National Institute of Cancer Prevention and Research (NICPR), Noida and Delhi. 

Project: AccEEND TB, India.

2) Board of Studies Member - Master’s in Clinical Research and Experimental Medicine, School of Allied and Health Sciences, Malla Reddy University, Hyderabad.

3) Book reviewer - BSP Publications, Pharma Med Press and Kakatiya Publications.

Current Position: International
PhD Researcher and Early Stage Researcher participant
Project: FIP 7 programme of EuroAgeism H2020 project, involving 13 European and Non-European countries.

Early-Stage Researcher (ESR) Participant, Euro Ageism H2020, Faculty of Pharmacy in Hradec Králové, Charles University, Europe.

Thesis: Polypharmacy and comparison of differences in potentially inappropriate prescribing in India, Ethiopia, and European countries.
Projects and Grants handled: 

• Project: FIP 7 programme of EuroAgeism H2020 project, involving 13 European and Non-European countries.

Grant: European Commission, FIP7 program Euro Ageism H2020-764632-MSCA-ITN supported by the scientific group “Ageing and Changes in the Therapeutic Values of Drugs in the Aged”, Charles University, Progress Programme Q42, SVV program 260 417.
Total Finance - 232 422,48 EU (Detailed budget - not disclosed)
EU Consortium: Israel, Czech Republic (CZ), UK, Poland, Netherlands, Sweden, Finland, Belgium.
Participating countries: Czech Republic, Serbia, Croatia, Bulgaria, Estonia, Turkey, Spain, Ireland, Belgium, India, Ethiopia.
Collaborating Institutions: Alliance Health and Social Care Alliance Scotland (AL), EMDA – The Alzheimer’s Association Israel (AAI), European Centre for Social Welfare Policy and Research (Euro Centre), National University of Ireland Galway (NUIG), United Nations Economic Commission for Europe (UNECE) and World Health Organization (WHO).

• Project No. START/MED/093

Thesis: Rational geriatric pharmacotherapy, medication errors and clinical pharmacy services in long-term care.
Total Finance - 2,299,968 CZK (Personal cost-1,353,600; Mentor remuneration-40,000; Travel costs-361,000; Training costs- 120,000; Costs of non-investment equipment, materials etc. - 80,000; Overhead costs - 345,368)
Grant: Charles University, Research Unit “Ageing, Polypharmacy and Changes in the Therapeutic Value of Drugs in the AgeD”, United Nations Economic Commission for Europe and World Health Organization, University of Zagreb, Croatia, University of Belgrade.

Previous Positions: National

1)Project Technical Support - III (Field Investigator) - Indian Council of Medical Research (ICMR) - National Institute of Nutrition (NIN), Hyderabad, India. 

Project: Strengthening the Monitoring of Tuberculosis Elimination in India - District Level Sentenial Survey (DLSS), India.

2) Associate Consultant (Epidemiology and Outcomes Research) - Bridge Medical Consulting Pvt. Ltd, New Delhi. 

3) Team Leader - Indian Council of Medical Research (ICMR) – National Institute of Nutrition (NIN), Hyderabad, India.

Project: National Sero-surveillance to monitor the trend of SARS-CoV-2 infection transmission in India.

4) Investigator (Field) - Indian Council of Medical Research (ICMR) – National Institute for Research in Tuberculosis (NIRT), Chennai, India.

Project: National survey for the state-wise prevalence of microbiologically confirmed pulmonary tuberculosis in India.

5) Assistant Professor and Clinical Preceptor: Vaagdevi Institute of Pharmaceutical Sciences, Warangal, India. 

No. of Research Publications: 18
Cumulative Impact Factor: 153
Number of Citations: 3000+

h-index: 14; i-10 index: 15 

Awarded grants: Total 7 (International: 6, National: 1)
Achievements: Total 9 (International: 5, National: 4)
My Interviews in Magazines and Newsletters: 3 (International: 2, National: 1)

Scientific presentations: (International: 11, National: 8)
Book reviews: 9 (International: 2, National: 7)
Guest Lectures: Total 3 (International: 1, National: 2)
Editorial member and reviewer: 8
Certification courses: Total 10 (2 - Stanford University, 8 - National and International Organizations)
Countries affiliated: USA, Italy, Poland, Slovak Republic, The Czech Republic, Germany, Hong Kong and 10 other European countries.

International collaborative research: Early Stage Researcher participant in the FIP 7 programme of EuroAgeism H2020 project under Marie-Curie Innovative Network and EU COST Action IS1402 network aimed at describing main prescribing problems in rational geriatric pharmacotherapy in 13 European and Non- European countries (including India and Ethiopia). 

Collaborating Institutions: Alliance: Health and Social Care Alliance Scotland (AL), EMDA – The Alzheimer’s Association Israel (AAI), European Centre for Social Welfare Policy and Research (EuroCentre), National University of Ireland Galway (NUIG), United Nations Economic Commission for Europe (UNECE) and World Health Organization (WHO).

Remarkable Achievements:

1. Award and Position: Early Stage Researcher (ESR) participant in the network of FIP7 EuroAgeism H2020 – ITN project, European Commission.
2. Reviewer: Acknowledged in Davidson’s Principles and Practice of Medicine textbook, 23rd Edition, 2018; Elsevier publishers ISBN: 9780702070280.
3. Personal interview: “I expect the 8-star Pharmacist Concept of World Health Organization will come true in India in the Future” published in an International Magazine “Lekarnicke Listy”, March 2018, Bratislava, Slovak Republic.
4. Best reviewer award: Textbook of Hutchison’s Clinical Methods 23rd International Edition by Michael Glynn &William Drake. Saunders Publishers, UK ISBN: 978-0-7020-4091
5. ERASMUS+ Student Mobility: Internship in various European countries.

A few other Achievements:

1. Award and Interview: Winner of “Ideathon” First Nobel Prize Series in India, Department of Biotechnology, India. Interview entitled “Pharmacist Nobel Prize Series: Science Impacts Lives – The Pride of India”, Indian Pharmaceutical Association – Community Pharmacy Division (IPA - CPD) e-Times 6 (2), March – April 2017.

2. Story of Success (2017): Published by Elsevier, as a part of the budding Medicos National contest.

3. Elsevier Student Ambassador (ESA) and Mentor’ for South Asia from July 2014 to June 2016.

4. Felicitation and award: Special Faculty Achievement Award at Viswambhara Educational Society Silver Jubilee Celebrations, March 2018, Warangal, India.

5. Award: Pharmacy Practice contribution award on World Pharmacist’s Day, 25th September 2017 for the successful delivery of an invited lecture on the Prescriptive role of Clinical Pharmacist in Ambulatory Care at Deccan School of Pharmacy, Hyderabad, India.

Acknowledgement: 

• I thank Prof. Daniela Fialova, PharmD, PhD, BCCP; Chair of the Horizon 2020 EuroAgeism FIP7 program; Head of the University Centre of Clinical Pharmacy, Faculty of Pharmacy, Charles University; Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University, Department of Geriatrics and Gerontology,1st Faculty of Medicine, Charles University, Czech Republic.
• Dr Akshaya Srikanth Bhagavathula, PharmD, PhD; Associate Professor of Epidemiology, Department of Public Health, North Dakota State University, United States of America. 
• Prof. Yamsani Madhusudan Rao, M.Pharm, PhD; Director, Vaagdevi group of Pharmacy Colleges, Warangal, India for their valuable guidance and support throughout my career.

 

Hypertension : Explained Clearly by World class Instructors

Dear Readers..!!! Thanks for visiting my blog...!!!

Click on the image to view clearly

JNC - VIII Evidence Based Guidelines

For more Updates, follow us on Facebook. 

Happy Blogging...!!!

Regards,

Deepak Kumar Bandari,

Pharm.D Intern,

Vaagdevi College of Pharmacy - India

Elsevier Student Ambassador - South Asia

2015 Treatment Recommendations on Emergency Cardiovascular Care Science and CPR

Dear Readers..!!! Thanks for visiting my blog...!!!

The International Liaison Committee on Resuscitation (ILCOR) was formed in 1993 and currently includes representatives from the American Heart Association (AHA), the European Resuscitation Council, the Heart and Stroke Foundation of Canada, the Australian and New Zealand Committee on Resuscitation, the Resuscitation Council of Southern Africa, the InterAmerican Heart Foundation, and the Resuscitation Council of Asia.

Mission : To identify and review international science and information relevant to cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC) and to offer consensus on treatment recommendations. ECC includes all responses necessary to treat sudden life-threatening events affecting the cardiovascular and respiratory systems, with a particular focus on sudden cardiac arrest. For this 2015 consensus publication, ILCOR also included first aid topics in its international review and consensus recommendations.

In 1999, the AHA hosted the first ILCOR conference to evaluate resuscitation science and develop common resuscitation guidelines. The conference recommendations were published in the Guidelines 2000 for CPR and ECC. Since 2000, researchers from the ILCOR member councils have evaluated and reported their International Consensus on CPR and ECC Science With Treatment Recommendations (CoSTR) in 5-year cycles. The conclusions and recommendations of the 2010 CoSTR were published at the end of 2010. Since that time, ILCOR meetings and webinars have continued to identify and evaluate resuscitation science. The most recent ILCOR 2015 International Consensus Conference on CPR and ECC Science With Treatment Recommendations was held in Dallas in February 2015, and this publication contains the consensus science statements and treatment recommendations developed with input from the ILCOR task forces, the invited participants, and public comment.

The parts of this CoSTR publication include a summary of the ILCOR processes of evidence evaluation and management of potential or perceived conflicts of interest, and then reports of the consensus of the task forces on adult basic life support (BLS; including CPR quality and use of an automated external defibrillator [AED]); advanced life support (ALS; including post–cardiac arrest care); acute coronary syndromes (ACS); pediatric BLS and ALS; neonatal resuscitation; education, implementation, and teams (EIT); and first aid. The 2015 CoSTR publication is not a comprehensive review of every aspect of resuscitation medicine; not all topics reviewed in 2010 were rereviewed in 2015. This Executive Summary highlights the evidence evaluation and treatment recommendations of this 2015 evidence evaluation process. Not all relevant references are cited here, because the detailed systematic reviews are included in the individual Parts of the 2015 CoSTR publication.

Here are the complete details on the therapeutic recommendations on CPR and Emergency Cardiovascular Care Science. 

Part - I: Executive Summary : Download Here

Part - II: Evidence Evaluation and Management of Conflicts of Interest : Download Here

Part - III: Adult Basic Life Support and Automated External Defibrillation : Download Here

Part - IV: Advanced Life Support : Download Here

Part - V: Acute Coronary Syndromes : Download Here

Part - VI: Pediatric Basic Life Support and Pediatric Advanced Life Support : Download Here

Part - VII: Neonatal Resuscitation : Download Here

Part - VIII: Education, Implementation, and Teams : Download Here

Part - IX: First Aid : Download Here

Wishing you success!!!

For more Updates, follow us on Facebook. 

Happy Blogging...!!!

Regards,

Deepak Kumar Bandari,

Pharm.D Intern,

Vaagdevi College of Pharmacy - India

Elsevier Student Ambassador - South Asia

Evidence Based Medicine - Pharmacist for Better Clinical Practice

Dear Readers..!!! Thanks for visiting my blog...!!!

Evidence-based medicine (EBM) is a process of systematically reviewing, appraising and using clinical research findings to aid the delivery of optimum clinical care to patients. In 1990's the term Evidence Based Medicine was introduced by "David Sackett and Gordon Guyatt". EBM includes the production of evidence through research and scientific review; production of evidence based clinical guidelines; Implementation of evidence-based, cost-effective practice through education and management; Strategical calculation of outcomes through evaluation of compliance. 

The Cochrane Library serves as the most valuable single access point with high-quality, independent evidence to inform healthcare decision-making. The various databases of Cochrane library includes: 

1. The Cochrane Database of Systematic Reviews : 3625 reviews and 1921 protocols.
2. The Database of Abstracts of Reviews of Effects (DARE) : 9025 systemic reviews.
3. The Cochrane Central Register of Controlled Trials :  550,000 studies.
4. The Health Technology Assessment Database : 7,528 health technology assessments.
5. The National Health Service (NHS) Economic Evaluation Database : 24,451 critical appraisals.

SIGN classification of grading Evidence: 

• 1++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias.
• 1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias.
• 1– Meta-analyses, systematic reviews, or RCTs with a high risk of bias.
• 2++ High-quality systematic reviews of case-control or cohort studies High-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal.
• 2+ Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal.
• 2– Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal.
• 3 Non-analytic studies; for example, case reports, case series.
• 4 Expert opinion.

Download Here 

Views of Pharmacist: 

Being an active part of health care system every pharmacist strives to provide the best possible care for patients. However, it is not always possible to translate the current developments into clinical practice. Although pharmacotherapy can be beneficial in all the patients, it can also lead to drug-related problems (DRPs), including untreated indications, drug use without an indication, improper drug selection, subtherapeutic dosage, overdosage, medication error, medication nonadherence, drug interactions, adverse drug reactions, adverse drug withdrawal events, and therapeutic failure. Clinical pharmacy services have a positive impact on drug-related problems and health outcomes reducing the burden and improving the quality of life of patient through Evidence based practice.

For more Updates, follow us on Facebook. 

Happy Blogging...!!!

Regards,

Deepak Kumar Bandari,

Pharm.D Intern,

Vaagdevi College of Pharmacy - India

Elsevier Student Ambassador - South Asia